News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
The GMP certificate is valid for three years until April 2024.
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
Subscribe To Our Newsletter & Stay Updated
